Lonza’s Capsugel Colorista capsule R&D solution can cut overall development time and offers greater flexibility during technical color development.
Lonza Pharma & Biotech’s new capsule R&D solution, Capsugel Colorista, can help drug developers cut overall development time while retaining greater flexibility during the technical development stage of coloration and before commitment to a final commercial coloring decision.
The capsules contain a variety of colorants usable in major markets and are available in different sizes for a range of doses and formulations. The company offers 150 color options in Coni-Snap gelatin capsules and more than 50 color options in Vcaps Plus capsules, for hydroxypropyl methylcellulose.
“A common issue faced by drug product developers is that the color composition choice for the commercial drug product is often made after initial stability studies,” said Emmanuelle Saugues, Color Lab EMEA supervisor for Lonza, in an Aug. 31, 2018 press release. “If new colors are introduced, it may require additional studies, which can result in costly delays. To address this problem, we have developed Colorista capsules at the Capsugel Color Lab.”
Source:
about 8 years ago
Preventing Microbial Contamination of Viral Vaccines and Vectorsabout 8 years ago
Retirement for Obsolete Heavy Metals Testsabout 8 years ago
Instrument Offers Simplified Weighing Processes and Accurate Resultsabout 8 years ago
Reaction Biology and Promega Partner on Bioassay Toolabout 8 years ago
New Software Tools Enhance Real-Time Process Monitoring in Labsabout 8 years ago
Stream Bio, 2BScientific Launch New Bioimaging Probesabout 8 years ago
Lonza Announces Technology for Automated Endotoxin Testingabout 8 years ago
SGS Implements Advanced Techniques for PBMCs
